Part of Firalis GroupHuningue · France

COVIRNA presents its results at its final conference in Brussels

Built on the Firalis FiMICS® panel of cardiac RNAs, the European project COVIRNA closed with a final conference in Brussels on April 19, 2023.

News

All media
COVIRNA final conference banner: improving personalised care and patient outcomes through molecular diagnostics and therapy, 19 April 2023, Brussels.
Announcement of the COVIRNA final conference, Brussels, 19 April 2023.

The last COVIRNA conference took place in Brussels on 19 April 2023, after 30 months of collaboration. The partners presented the project’s results, including the database built from patient data, and shared what they had learned about bringing RNA-based molecular methods into personalised diagnosis and therapy. Discussions also covered the product development of the COVIRNA toolkit and its possible use in long COVID and other diseases.

About the project

COVIRNA was set up in response to the COVID-19 pandemic. Its goal was a prognostic test to identify COVID-19 patients at risk of fatal cardiovascular complications, so that their monitoring and care could be adapted.

  • Coordinator: Luxembourg Institute of Health (LIH)
  • Consortium: 15 partners from healthcare, academia and industry, in 12 European countries
  • Start: 1 November 2020

The project was built on FiMICS®, the Firalis panel that measures long non-coding RNAs (lncRNAs) enriched in the heart. Firalis was in charge of measuring the lncRNA biomarkers and of turning them into an in vitro diagnostic kit.

Source Firalis project news, 7 April 2023, and COVIRNA launch announcement, 27 November 2020.

Media enquiries

Writing about Firalis? Our media contact sits with Firalis Group.

Opens in a new tab